Alnylam Pharmaceuticals (NASDAQ: ALNY) Financial Health: ROIC vs. WACC Analysis

Font: Financial Modeling Prep  • Jun 17, 2026

• Alnylam Pharmaceuticals demonstrates robust financial efficiency, with its Return on Invested Capital (ROIC) significantly exceeding its Weighted Average Cost of Capital (WACC).
• The comparison of ROIC to WACC serves as a critical indicator of a company's ability to create shareholder value.
• In contrast to Alnylam, several biopharmaceutical peers exhibit lower or negative ROIC values, suggesting challenges in value creation or typical early-stage development dynamics.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company that focuses on developing a class of medicines called RNAi therapeutics. The company operates in a very competitive field where it competes with other firms to develop and market new drugs. A company's financial health is a key indicator of its potential.

To measure a company's financial health, we can compare its Return on Invested Capital (ROIC) with its Weighted Average Cost of Capital (WACC). ROIC measures how well a company generates cash flow relative to the capital it has invested. WACC is the average rate of return a company is expected to pay to its investors.

Alnylam demonstrates strong financial efficiency with an ROIC of 19.66%, which is much higher than its WACC of 5.85%. This gives it an ROIC to WACC ratio of 3.36. This means Alnylam is generating returns more than three times its cost of capital, which is a strong sign of value creation for its shareholders.

In comparison, Alnylam's peers are not performing as well. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has an ROIC of 3.92% and a WACC of 5.19%, resulting in a ratio of 0.76. This shows that BioMarin is not yet creating value, as its returns are lower than its cost of capital.

Other peers like Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), Sarepta Therapeutics, Inc. (NASDAQ: SRPT), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) all have negative ROIC values. This indicates that these companies are currently destroying shareholder value, a situation often seen in biopharmaceutical companies that are still in their development and growth stages.